GAROFALO HEALTH CARE S.P.A. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.72 EUR | 0.00% |
|
-1.87% | +1.72% |
| Mar. 14 | GHC, revenues up but profit falls after Aurelia acquisition | AN |
| Mar. 14 | Garofalo Health Care S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 46% by 2025.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +1.72% | 447M | B | ||
| -24.40% | 15.4B | B+ | ||
| +1.80% | 12.12B | B | ||
| +2.82% | 11.43B | B+ | ||
| +10.99% | 10.84B | B+ | ||
| +24.10% | 8.29B | B | ||
| -0.40% | 7.78B | A- | ||
| +22.90% | 7.33B | D | ||
| +5.73% | 6.75B | B- | ||
| +50.39% | 4.65B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- GHC Stock
- Ratings Garofalo Health Care S.p.A.
